- Home
- BFRI vs LYRA Comparison
BFRI vs LYRA Comparison
Compare BFRI & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFRI
- LYRA
- Stock Information
- Founded
- BFRI 1997
- LYRA 2005
- Country
- BFRI United States
- LYRA United States
- Employees
- BFRI N/A
- LYRA N/A
- Industry
- BFRI Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- BFRI Health Care
- LYRA Health Care
- Exchange
- BFRI Nasdaq
- LYRA Nasdaq
- Market Cap
- BFRI 7.5M
- LYRA 7.4M
- IPO Year
- BFRI 2021
- LYRA 2020
- Fundamental
- Price
- BFRI $0.56
- LYRA $4.93
- Analyst Decision
- BFRI Strong Buy
- LYRA Buy
- Analyst Count
- BFRI 1
- LYRA 2
- Target Price
- BFRI $2.75
- LYRA $2.00
- AVG Volume (30 Days)
- BFRI 174.6K
- LYRA 152.5K
- Earning Date
- BFRI 05-15-2025
- LYRA 05-06-2025
- Dividend Yield
- BFRI N/A
- LYRA N/A
- EPS Growth
- BFRI N/A
- LYRA N/A
- EPS
- BFRI N/A
- LYRA N/A
- Revenue
- BFRI $37,997,000.00
- LYRA $1,185,000.00
- Revenue This Year
- BFRI $18.57
- LYRA N/A
- Revenue Next Year
- BFRI $20.17
- LYRA $1,286.17
- P/E Ratio
- BFRI N/A
- LYRA N/A
- Revenue Growth
- BFRI 14.28
- LYRA N/A
- 52 Week Low
- BFRI $0.54
- LYRA $3.81
- 52 Week High
- BFRI $2.22
- LYRA $17.20
- Technical
- Relative Strength Index (RSI)
- BFRI 29.93
- LYRA 47.13
- Support Level
- BFRI $0.58
- LYRA $3.81
- Resistance Level
- BFRI $0.68
- LYRA $5.50
- Average True Range (ATR)
- BFRI 0.06
- LYRA 0.95
- MACD
- BFRI -0.01
- LYRA 0.03
- Stochastic Oscillator
- BFRI 11.21
- LYRA 24.40
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.